Prothena (PRTA) Expected to Announce Quarterly Earnings on Thursday

Prothena (NASDAQ:PRTA) is expected to be announcing its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect Prothena to post earnings of ($0.45) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Prothena Stock Down 0.3%

PRTA opened at $8.93 on Thursday. The firm’s 50-day moving average price is $9.48 and its 200-day moving average price is $9.31. The company has a market cap of $480.70 million, a P/E ratio of -1.71, a price-to-earnings-growth ratio of 1.89 and a beta of -0.11. Prothena has a 52-week low of $4.32 and a 52-week high of $16.67.

Hedge Funds Weigh In On Prothena

A number of hedge funds have recently modified their holdings of the business. Rubric Capital Management LP acquired a new position in Prothena in the third quarter valued at about $15,034,000. Rangeley Capital LLC purchased a new position in shares of Prothena during the 2nd quarter worth approximately $4,342,000. Arrowstreet Capital Limited Partnership acquired a new stake in Prothena in the 3rd quarter valued at approximately $6,386,000. JPMorgan Chase & Co. raised its position in Prothena by 479.6% in the third quarter. JPMorgan Chase & Co. now owns 735,765 shares of the biotechnology company’s stock valued at $7,181,000 after purchasing an additional 608,814 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in Prothena by 164.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 935,333 shares of the biotechnology company’s stock worth $8,932,000 after purchasing an additional 582,112 shares in the last quarter. 97.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on PRTA shares. Citizens Jmp boosted their price objective on shares of Prothena from $11.00 to $19.00 and gave the company a “market outperform” rating in a report on Monday, December 1st. Royal Bank Of Canada boosted their target price on shares of Prothena from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 7th. Citigroup reissued a “market outperform” rating on shares of Prothena in a report on Monday, December 1st. Chardan Capital raised shares of Prothena to a “strong-buy” rating in a report on Wednesday, November 19th. Finally, UBS Group set a $36.00 target price on shares of Prothena in a research note on Tuesday, October 28th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $21.56.

Prothena Company Profile

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.